NCT05052099View on ClinicalTrials.gov

Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions
Biliary Tract Cancer
Interventions
DRUG

mFOLFOX6, Atezolizumab and Bevacizumab

"All study medication is administered by intravenous (IV) infusion on Day 1 of each 14-day cycle:~• mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form \[levo leucovorin\]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2~combined with~* Atezolizumab 840 mg and~* Bevacizumab 10 mg/kg"

Trial Locations (2)

31008

Clínica Universidad de Navarra, Pamplona

45147

Universitätsklinikum Essen, Essen

All Listed Sponsors
lead

University Hospital, Essen

OTHER

NCT05052099 - Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter